$330M Oversubscribed: Ollin’s Faricimab Challenger Just Became the Most Funded Retinal Disease Bet of 2026
Ollin Biosciences closed an oversubscribed $330M Series B on June 24 to run global Phase 3 trials of OLN324...
competitive intelligence
The Six-Month Shot That Broke HIV’s Business Model: Lenacapavir Is Rewriting Who Wins in a Market Everyone Thought Was Settled
Gilead's lenacapavir approval for HIV PrEP—100% efficacy, twice-yearly dosing—threatens daily-pill incumbents and signals a mechanism arms race across the...
AI Rewires Biopharma BD — From Data Grunt to Strategic Lever
At BIO-Europe Spring 2026, a cross-sector panel dissected how generative AI is restructuring the business development workflow — from...